drugset / Trial / NCT00951301

Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

NCT00951301 ↗

Phase 1 Terminated 143 enrolled Mayo Clinic
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being done to see if the addition of mangosteen juice to standard medical care will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC) cardioversion. The study will also look at the effects the mangosteen juice may have on biomarkers of inflammation and endothelial cell dysfunction (the tissue lining the arteries does not function properly).

Timeline

Start
2009-07
Primary completion
2013-06
Completion
2013-06

Outcome

Outcome not reported

Stopped (Enrollment): “Significantly lower accrual rate than anticipated, time constraints.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mangosteen Unknown 6 unknown —

Indications